| scholarly article | Q13442814 |
| P2093 | author name string | Kit S Lam | |
| Primo N Lara | |||
| Chao Jian | |||
| Ai-Xi Yu | |||
| Qianyu Zhang | |||
| Ai-Ming Yu | |||
| Zhijian Duan | |||
| Theodore Wun | |||
| Mei-Juan Tu | |||
| Pui Yan Ho | |||
| Jing-Xin Qiu | |||
| Ralph W DeVere White | |||
| P2860 | cites work | Bioengineering of noncoding RNAs for research agents and therapeutics | Q26772092 |
| Children's Oncology Group's 2013 blueprint for research: bone tumors | Q27027664 | ||
| A perspective on cancer cell metastasis | Q28307891 | ||
| Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes | Q30434616 | ||
| MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo | Q34211970 | ||
| N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. | Q34260260 | ||
| Osteosarcoma treatment - where do we stand? A state of the art review. | Q34392457 | ||
| Low miR-34a and miR-192 are associated with unfavorable prognosis in patients suffering from osteosarcoma | Q35137803 | ||
| A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications | Q35476690 | ||
| Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity. | Q35745244 | ||
| Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy | Q35894540 | ||
| Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization | Q35897815 | ||
| Mouse models of advanced spontaneous metastasis for experimental therapeutics | Q35966786 | ||
| Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells | Q36414039 | ||
| New signals from the invasive front | Q36488744 | ||
| Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth | Q36497652 | ||
| Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy | Q36557246 | ||
| Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine | Q36562114 | ||
| MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression | Q36746921 | ||
| PDL1 Regulation by p53 via miR-34 | Q36887608 | ||
| Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest | Q36928436 | ||
| Bioengineered non-coding RNA agent (BERA) in action | Q37391959 | ||
| Osteosarcoma treatment: state of the art. | Q37392078 | ||
| gammaH2AX: a sensitive molecular marker of DNA damage and repair | Q37687078 | ||
| Osteosarcoma: review of the past, impact on the future. The American experience | Q37705055 | ||
| Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial | Q37809940 | ||
| Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature | Q37860966 | ||
| Translational biology of osteosarcoma | Q38260633 | ||
| Targeting metastasis | Q38786658 | ||
| Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells | Q38801405 | ||
| Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma? | Q38875793 | ||
| The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression | Q38926069 | ||
| Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia | Q38929504 | ||
| miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 | ||
| Functional characterization of osteosarcoma cell lines provides representative models to study the human disease | Q39553187 | ||
| Establishment and characterization of a new highly metastatic human osteosarcoma cell line | Q39861409 | ||
| miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells | Q39917469 | ||
| Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. | Q40192837 | ||
| An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis | Q40371637 | ||
| Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings | Q44317895 | ||
| Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols | Q44438560 | ||
| c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells | Q47588979 | ||
| Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study | Q73936652 | ||
| Combination therapies in oncology | Q87212972 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 30742-30755 | |
| P577 | publication date | 2017-03-18 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models | |
| P478 | volume | 8 |
| Q61810563 | Bioengineered Let-7c Inhibits Orthotopic Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity |
| Q93016104 | Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics |
| Q92672846 | Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs |
| Q92190037 | Current trends in drug metabolism and pharmacokinetics |
| Q90290617 | Down-Regulated microRNA-34a Expression as a Prognostic Marker for Poor Osteosarcoma in Mice: A Systematic Review and Meta-Analysis |
| Q64279445 | Drug resistance-related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies |
| Q44463289 | MicroRNA-34a: A Versatile Regulator of Myriads of Targets in Different Cancers. |
| Q99417440 | RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges |
| Q90309160 | RNA therapy: Are we using the right molecules? |
| Q94564366 | Transcription and Translation Inhibitors in Cancer Treatment |
Search more.